These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 24599398)
1. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Ducasse D; Boyer L; Michel P; Loundou A; Macgregor A; Micoulaud-Franchi JA; Courtet P; Abbar M; Leboyer M; Fond G Psychopharmacology (Berl); 2014 Sep; 231(18):3765-70. PubMed ID: 24599398 [TBL] [Abstract][Full Text] [Related]
2. The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D Egashira N; Kubota N; Goto Y; Watanabe T; Kubota K; Katsurabayashi S; Iwasaki K Pharmacol Biochem Behav; 2018 Feb; 165():9-13. PubMed ID: 29273456 [TBL] [Abstract][Full Text] [Related]
3. Computational modelling reveals contrasting effects on reinforcement learning and cognitive flexibility in stimulant use disorder and obsessive-compulsive disorder: remediating effects of dopaminergic D2/3 receptor agents. Kanen JW; Ersche KD; Fineberg NA; Robbins TW; Cardinal RN Psychopharmacology (Berl); 2019 Aug; 236(8):2337-2358. PubMed ID: 31324936 [TBL] [Abstract][Full Text] [Related]
4. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents. Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101 [TBL] [Abstract][Full Text] [Related]
5. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Stone JM; Davis JM; Leucht S; Pilowsky LS Schizophr Bull; 2009 Jul; 35(4):789-97. PubMed ID: 18303092 [TBL] [Abstract][Full Text] [Related]
6. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. McCormick PN; Wilson VS; Wilson AA; Remington GJ Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779 [TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics: mechanism of action. Seeman P Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT. Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402 [TBL] [Abstract][Full Text] [Related]
9. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [ Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210 [TBL] [Abstract][Full Text] [Related]
10. Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation. Morein-Zamir S; Craig KJ; Ersche KD; Abbott S; Muller U; Fineberg NA; Bullmore ET; Sahakian BJ; Robbins TW Psychopharmacology (Berl); 2010 Oct; 212(3):357-67. PubMed ID: 20661550 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458 [TBL] [Abstract][Full Text] [Related]
15. Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Denys D; de Vries F; Cath D; Figee M; Vulink N; Veltman DJ; van der Doef TF; Boellaard R; Westenberg H; van Balkom A; Lammertsma AA; van Berckel BN Eur Neuropsychopharmacol; 2013 Nov; 23(11):1423-31. PubMed ID: 23876376 [TBL] [Abstract][Full Text] [Related]
16. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range. Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Tadori Y; Kikuchi T Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121 [TBL] [Abstract][Full Text] [Related]
18. Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Schotte A; Janssen PF; Bonaventure P; Leysen JE Histochem J; 1996 Nov; 28(11):791-9. PubMed ID: 8968731 [TBL] [Abstract][Full Text] [Related]
19. Protocol for a Systematic Review and Meta-Analysis of Lithium, Anticonvulsive or atypical antipsychotic Drugs for Treatment of Refractory Obsessive-Compulsive Disorder. Soleimani R; Jalali MM; Keshtkar A; Jalali SM J Med Life; 2017; 10(4):208-215. PubMed ID: 29362595 [TBL] [Abstract][Full Text] [Related]
20. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Zhang W; Bymaster FP Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]